Immunocore Holdings (IMCR) Aktievy
Immunocore Holdings plc, tillsammans med sina dotterbolag, bedriver utveckling och kommersialisering av immunmodulerande läkemedel för patienter med cancer, infektionssjukdomar och autoimmuna sjukdomar i USA, Europa och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 4/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 4/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
Inga risker upptäckta för IMCR från våra riskkontroller.
IMCR Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Immunocore Holdings plc Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$28.83 |
| 52 veckors högsta | US$40.71 |
| 52 veckors lägsta | US$27.56 |
| Beta | 0.74 |
| 1 månads förändring | -1.60% |
| 3 månaders förändring | -12.45% |
| 1 års förändring | -7.48% |
| 3 års förändring | -49.60% |
| 5 års förändring | -29.68% |
| Förändring sedan börsintroduktionen | -33.26% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • May 19
IMCR: Future Upside Will Depend On Risky Oncology Pipeline Execution
Analysts now set Immunocore Holdings' fair value at $34, up $1 from $33. This reflects adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E after recent Street research highlighted a more cautious view on upside without clearer pipeline progress.Uppdatering av berättelse • Apr 25
IMCR: Pipeline Upside Will Rely On Higher Risk Oncology Programs
Analysts cut their price target on Immunocore Holdings to $33 from $48, noting that Kimmtrak provides an established revenue base in uveal melanoma. They indicated that the investment case now depends more on what they view as higher risk pipeline outcomes.Recent updates
Uppdatering av berättelse • May 19
IMCR: Future Upside Will Depend On Risky Oncology Pipeline Execution
Analysts now set Immunocore Holdings' fair value at $34, up $1 from $33. This reflects adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E after recent Street research highlighted a more cautious view on upside without clearer pipeline progress.Uppdatering av berättelse • Apr 25
IMCR: Pipeline Upside Will Rely On Higher Risk Oncology Programs
Analysts cut their price target on Immunocore Holdings to $33 from $48, noting that Kimmtrak provides an established revenue base in uveal melanoma. They indicated that the investment case now depends more on what they view as higher risk pipeline outcomes.Uppdatering av berättelse • Apr 08
IMCR: Pipeline Risk And Sector Rotation Will Shape Balanced 2026 Outlook
Analysts have reset their average price target on Immunocore to $33. Some frame this move as a sign that Kimmtrak's uveal melanoma revenue potential is closer to peak, with future upside hinging more on higher risk pipeline assets, while others still see room for value in the broader small to mid cap biotech group.Uppdatering av berättelse • Mar 24
IMCR: Sector Rotation And Pipeline Risk Will Shape Balanced 2026 Outlook
Narrative Update The analyst fair value estimate for Immunocore Holdings has shifted from $38 to $33. This change reflects mixed Street views, with some analysts highlighting Kimmtrak's moderate market and maturing sales, while others point to broader biotech sentiment and pipeline potential as key factors for future returns.Uppdatering av berättelse • Mar 10
IMCR: Sector Rotation And Capital Production Shift Will Shape Bullish 2026 Outlook
Analysts have nudged their fair value estimate for Immunocore Holdings up from $37.00 to $38.00, citing higher Street price targets from $40 to $55. These targets reflect growing confidence in small to mid cap biotech as some companies are seen as shifting from capital consumers to capital producers and benefiting from improving sector sentiment.
Uppdatering av berättelse • Feb 24
IMCR: Bullish View Will Center On 2026 Capital Producer Transition
Analysts have nudged their average price target on Immunocore higher, with recent moves such as a lift to $40 and an upgrade anchored by a new $55 target. These changes support a small upward adjustment in our modeled fair value to $66.57, alongside slightly higher discount rate and P/E assumptions.Uppdatering av berättelse • Feb 08
IMCR: Sector Rotation And Pipeline Execution Will Shape Bullish 2026 Outlook
Narrative Update on Immunocore Holdings Analysts have lifted their average price target for Immunocore to a range anchored by the recent US$40 and US$55 targets. This reflects updated assumptions on discount rates, revenue growth, profit margins, and future P/E multiples as they factor in improving sentiment toward small to mid cap biotech names.Uppdatering av berättelse • Jan 24
IMCR: Balanced Outlook As Hepatitis B Data And Sector Rotation Shape 2026
Analysts have lifted their price target framework for Immunocore Holdings from about $24.93 to $37.00, reflecting recent Street research in which firms increased targets to as high as $55 and highlighted improving biotech fundamentals along with shifting investor attention toward small to mid cap commercial names. Analyst Commentary Recent Street research on Immunocore Holdings clusters around a common theme, with several firms linking their updated views to a broader shift in attention toward small to mid cap commercial biotech names.Uppdatering av berättelse • Jan 10
IMCR: Bullish View Will Center On Advancing HBV TCR Bispecific Program
Narrative Update Analysts have lifted their blended price target for Immunocore, with recent moves such as a Morgan Stanley increase to $40 and a UBS move to $55 contributing to a higher implied fair value of about $66.36, based on updated assumptions for growth, margins and a higher future P/E multiple. Analyst Commentary Recent Street research around Immunocore centers on shifting views of small to mid cap biotech, updated price targets, and how investors might think about the balance between potential upside and execution risk.Seeking Alpha • Nov 08
Immunocore: Continuing To Improve The Bottom Line, But Needing A Big Catalyst
Summary Immunocore still relies exclusively on sales of tebentafusp to fund operations. While these sales have supported the company, they have not been enough to achieve profitability. Current market sentiment says to "Hold" based on slowing sales growth, but this does not factor in the broad pipeline. To me, this is a qualified "Buy" assuming they can take any one of their many projects to the finish line. Read the full article on Seeking AlphaAnalysartikel • Aug 02
Immunocore Holdings (NASDAQ:IMCR) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Jun 10
Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Immunocore Holdings plc ( NASDAQ:IMCR ) shareholders have had their patience rewarded with a 27% share price jump in...Seeking Alpha • Apr 27
Immunocore Holdings: A Name On My Watch List
Summary Immunocore Holdings' shares have fallen over 60% since February 2024 due to lack of catalysts and competition for its main product, Kimmtrak. Kimmtrak, approved for metastatic uveal melanoma, faces market saturation and competition, but label expansion could significantly increase its market potential. Immunocore's pipeline includes promising early-stage oncology and infectious disease programs, but pivotal data for key trials won't be available until 2H26 or later. An analysis around Immuncore Holdings follows in the paragraphs below. Read the full article on Seeking AlphaAnalysartikel • Apr 26
Improved Revenues Required Before Immunocore Holdings plc (NASDAQ:IMCR) Shares Find Their Feet
Immunocore Holdings plc's ( NASDAQ:IMCR ) price-to-sales (or "P/S") ratio of 4.9x might make it look like a buy right...
Ny berättelse • Mar 23
AI Tools And Global Expansion Will Broaden KIMMTRAK's Market Reach
Expansion into less dense U.S. markets and international launches are key to driving revenue growth for Immunocore's KIMMTRAK.Analysartikel • Mar 04
Is Immunocore Holdings (NASDAQ:IMCR) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Feb 27
Immunocore: A Commercial Biotech Nearing Its Pivotal Break-Even Point
Summary Immunocore Holdings focuses on immunotherapy for oncology, with tebentafusp approved for metastatic uveal melanoma and brenetafusp in advanced trials. IMCR's strong balance sheet, with over $800 million in liquid assets, positions them well for future R&D or even a potential acquisition. Growth of tebentafusp sales has slowed, increasing reliance on new projects like brenetafusp, which carries inherent biotech industry risks. IMCR's financials show increased product revenue and net income, with substantial cash reserves to support ongoing and future developments. Read the full article on Seeking AlphaAnalysartikel • Jan 08
There Is A Reason Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Undemanding
Immunocore Holdings plc's ( NASDAQ:IMCR ) price-to-sales (or "P/S") ratio of 5.2x might make it look like a strong buy...Seeking Alpha • Dec 10
Immunocore Is Adequately Valued, But Its Prospects Are Uncertain
Summary Immunocore's KIMMTRAK, targeting metastatic uveal melanoma, is FDA-approved and has shown significant clinical efficacy, with potential label expansions in cutaneous and adjuvant uveal melanoma. The company's ImmTAX platform develops TCR-based bispecific molecules, with ongoing trials for Tebentafusp and Brenetafusp in various cancers, showing promising early results. Financially, Immunocore has a strong cash position and stable revenue growth, but concerns remain about the pipeline's strength and clarity. Despite recent stock declines and cautious market sentiment, future trial successes could make current prices attractive for conservative investors. Read the full article on Seeking AlphaAnalysartikel • Oct 24
Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Sep 19
Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry
Immunocore Holdings plc's ( NASDAQ:IMCR ) price-to-sales (or "P/S") ratio of 6.1x might make it look like a buy right...Seeking Alpha • Aug 12
Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal
Summary Immunocore Holdings is a biotech company with a promising revenue trajectory in 2024, driven by its leading product, KIMMTRAK. IMCR has a diverse pipeline with potential value drivers like IMC-F106C for cutaneous melanoma and IMC-M113V for HIV. The main risks stem from the Company's heavy reliance on KIMMTRAK and potential clinical trial failures for other pipeline drugs, such as IMC-F106C and IMC-M113V. I also believe IMCR could be a viable takeover target, given its diverse IP, growing revenues, and strong financials, which could potentially attract big pharma. Despite premium valuation risks, Immunocore's financials are robust, making it a "buy" for long-term investors familiar with biotech risks. Read the full article on Seeking AlphaAnalysartikel • Jul 24
Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Immunocore Holdings fair value estimate is US$58.75 Immunocore...Analysartikel • Jun 16
Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues
To the annoyance of some shareholders, Immunocore Holdings plc ( NASDAQ:IMCR ) shares are down a considerable 28% in...Analysartikel • May 11
Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • May 11
Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Immunocore Holdings plc ( NASDAQ:IMCR ) shareholders are probably feeling a little disappointed, since its shares fell...Analysartikel • Apr 05
Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Immunocore Holdings fair value estimate is US$83.30 Immunocore...Analysartikel • Jan 22
Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Jan 21
Immunocore Holdings: Vulnerable To Profit Taking After Big Rally
Summary Immunocore Holdings plc is a commercial-stage biotechnology company focused on developing immunotherapies for cancer, infectious, and autoimmune diseases. The company's stock is up around 80% since late October and now is solidly in mid-cap territory. The stock has gotten shout outs from Barron's and Robert W. Baird to start the new year. Are further gains ahead in 2024 for Immunocore shareholders? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaAnalysartikel • Dec 18
Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%
Immunocore Holdings plc ( NASDAQ:IMCR ) shares have had a really impressive month, gaining 37% after a shaky period...Aktieägarnas avkastning
| IMCR | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | 2.8% | 1.2% | 1.1% |
| 1Y | -7.5% | 34.6% | 28.7% |
Avkastning vs industri: IMCR presterade sämre än US Biotechs branschen som gav 34.6 % under det senaste året.
Avkastning vs Marknaden: IMCR presterade sämre än US marknaden som gav 28.7 % under det senaste året.
Prisvolatilitet
| IMCR volatility | |
|---|---|
| IMCR Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: IMCR har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: IMCR s veckovolatilitet ( 5% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1999 | 524 | Bahija Jallal | www.immunocore.com |
Immunocore Holdings plc, tillsammans med sina dotterbolag, bedriver utveckling och kommersialisering av immunmodulerande läkemedel för patienter med cancer, infektionssjukdomar och autoimmuna sjukdomar i USA, Europa och internationellt. Företaget erbjuder KIMMTRAK för behandling av inoperabelt eller metastaserat uvealt melanom. Företaget utvecklar också onkologiprogram, inklusive tebentafusp som befinner sig i klinisk fas 3-studie för behandling av avancerat kutant melanom och adjuvant uvealt melanom; brenetafusp som befinner sig i klinisk fas 3-studie för behandling av avancerat kutant melanom i första linjen och i klinisk fas 1/2-studie för behandling av olika tumörtyper; IMC-R117C som befinner sig i klinisk fas 1/2 för behandling av avancerade solida tumörer, såsom kolorektalcancer, och IMC-P115C som befinner sig i klinisk fas 1 för patienter med tumörer som uttrycker PRAME.
Immunocore Holdings plc Sammanfattning av grunderna
| IMCR grundläggande statistik | |
|---|---|
| Börsvärde | US$1.47b |
| Vinst(TTM) | -US$27.57m |
| Intäkter(TTM) | US$412.81m |
3.6x
P/S-förhållande-53.2x
P/E-förhållandeÄr IMCR övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| IMCR resultaträkning (TTM) | |
|---|---|
| Intäkter | US$412.81m |
| Kostnad för intäkter | US$13.47m |
| Bruttovinst | US$399.35m |
| Övriga kostnader | US$426.91m |
| Intäkter | -US$27.57m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.54 |
| Bruttomarginal | 96.74% |
| Nettovinstmarginal | -6.68% |
| Skuld/egenkapitalförhållande | 100.0% |
Hur har IMCR utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/24 21:59 |
| Aktiekurs vid dagens slut | 2026/05/22 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Immunocore Holdings plc bevakas av 27 analytiker. 15 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Jack Allen | Baird |
| Suranjit Mukherjee | BTIG |
| Justin Zelin | BTIG |